Repetitive Transcranial Magnetic Stimulation in Bulimia Nervosa: Preliminary Results of a Single-Centre, Randomised, Double-Blind, Sham-Controlled Trial in Female OutpatientsWalpoth M.a, b · Hoertnagl C.a, b · Mangweth-Matzek B.c · Kemmler G.a · Hinterhölzl J.a · Conca A.d · Hausmann A.a, b
aDepartment of General Psychiatry, bLaboratory for Magnetic Brain Stimulation, Department of General Psychiatry, and cDepartment of Psychosomatic Medicine, Innsbruck Medical University, Innsbruck, and dDepartment of General Psychiatry, Regional Hospital Rankweil, Rankweil, Austria
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Bulimia nervosa (BN) is often associated with depressive symptoms and treatment with antidepressants has shown positive effects. A shared deficient serotonergic transmission was postulated for both syndromes. The left dorsolateral prefrontal cortex was argued to regulate eating behaviour and to be dysfunctional in eating disorders. Methods: Fourteen women meeting DSM-IV criteria for BN were included in a randomised placebo-controlled double-blind trial. In order to exclude patients highly responsive to placebo, all patients were first submitted to a one-week sham treatment. Randomisation was followed by 3 weeks of active treatment or sham stimulation. As the main outcome criterion we defined the change in binges and purges. Secondary outcome variables were the decrease of the Hamilton Depression Rating Scale (HDRS), the Beck Depression Inventory (BDI) and the Yale-Brown Obsessive Compulsive Scale (YBOCS) over time. Results: The average number of binges per day declined significantly between baseline and the end of treatment in the two groups. There was no significant difference between sham and active stimulation in terms of purge behaviour, BDI, HDRS and YBOCS over time. Conclusion: These preliminary results indicate that repetitive transcranial magnetic stimulation (rTMS) in the treatment of BN does not exert additional benefit over placebo. A larger number of patients might clarify a further role of rTMS in the treatment of BN.
© 2008 S. Karger AG, Basel
- Faravelli C, Ravaldi C, Truglia E, Zucchi T, Cosci F, Ricca V: Clinical epidemiology of eating disorders: results from the Sesto Fiorentino study. Psychother Psychosom 2006;75:376–383.
- Russell G: Bulimia nervosa: an ominous variant of anorexia nervosa. Psychol Med 1979;9:429–448.
- Engler PA, Crowther JH, Dalton G, Sanftner JL: Predicting eating disorder group membership: an examination and extension of the sociocultural model. Behav Ther 2006;37:69–79.
- Milos GF, Spindler AM, Buddeberg C, Crameri A: Axes I and II comorbidity and treatment experiences in eating disorder subjects. Psychother Psychosom 2003;72:276–285.
- Fava M, Copeland PM, Schweiger U, Herzog DB: Neurochemical abnormalities of anorexia nervosa and bulimia nervosa. Am J Psychiatry 1989;146:963–971.
- Goldbloom DS, Garfinkel PE: The serotonin hypothesis of bulimia nervosa: theory and evidence. Can J Psychiatry 1990;35:741–744.
Bacaltchuk J, Hay P: Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev 2003;4:CD003391.
- Hudson JI, Mangweth B, Pope HG Jr, De Col C, Hausmann A, Gutweniger S, Laird N, Biebl W, Tsuang MT: Family study of affective spectrum disorder. Arch Gen Psychiatry 2003;60:170–177.
Andreason PJ, Altemus M, Zametkin AJ, King AC, Luciono J, Cohen RM: Regional cerebral glucose metabolism in bulimia nervosa. Am J Psychiatry 1993;149:1506–1513.
- Nozoe S, Naruo T, Yonekura R, Nakabeppu Y, Soejima Y, Nagai N, Nakajo M, Tanaka H: Comparison of regional cerebral blood flow in patients with eating disorders. Brain Res Bull 1995;36:251–255.
- Hausmann A, Pascual-Leone A, Kemmler G, Rupp CI, Lechner T, Kramer-Reinstadler K, Walpoth M, Mechtcheriakov S, Conca A, Weiss EM: No deterioration of cognitive performance in an aggressive unilateral and bilateral antidepressant rTMS add-on trial. J Clin Psychiatry 2004;65:772–782.
Paus T, Jech R, Thompson CJ, Comeau R, Peters T, Evans AC: Transcranial magnetic stimulation during positron emission tomography: a new method for studying connectivity of human cerebral cortex. J Neurosci 1997;7:3178–3184.
- Hausmann A, Mangweth B, Walpoth M, Hoertnagl C, Kramer-Reinstadler K, Rupp CI, Hinterhuber H: Repetitive transcranial magnetic stimulation in the double-blind treatment of a depressed patient suffering from bulimia nervosa: a case report. Int J Neuropsychopharmacol 2004;7:371–373.
- Hausmann A, Kemmler G, Walpoth M, Mechtcheriakov S, Kramer-Reinstadler K, Lechner T, Walch T, Deisenhammer EA, Kofler M, Rupp CI, Hinterhuber H, Conca A: No benefit derived from repetitive transcranial magnetic stimulation in depression: a prospective, single-centre, randomised, double-blind, sham-controlled ‘add-on’ trial. J Neurol Neurosurg Psychiatry 2004;75:320–322.
- Hamilton N: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
- Beck AT, Beamesderfer A: Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 1974;7:151–169.
Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale II: validity. Arch Gen Psychiatry 1989;49:1012–1016.
Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M: SKID-I. Strukturiertes klinisches Interview für DSM-IV. Göttingen, Hogrefe, 1997.
- Dunayevich E, Sax KW, Keck PE Jr, McElroy SL, Sorter MT, McConville BJ, Strakowski SM: Twelve-month outcome in bipolar patients with and without personality disorders. J Clin Psychiatry 2000;61:134–139.
- Hudson JI, McElroy SL, Raymond NC, Crow S, Keck PE, Carter WP, Mitchell JE, Strakowski SM, Pope HG, Coleman BS, Jonas JM: Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind study. Am J Psychiatry 1998;155:1756–1762.
- Pearlstein T, Spurell E, Hohlstein LA, Gurney V, Read J, Fuchs C, Keller MB: A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response. Arch Womens Ment Health 2003;6:147–151.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.